Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statem
- PDF / 2,438,463 Bytes
- 37 Pages / 595.276 x 790.866 pts Page_size
- 100 Downloads / 191 Views
REVIEW
Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement Ajitesh Roy . Animesh Maiti . Anirban Sinha . Arjun Baidya . Asish Kumar Basu . Dasarathi Sarkar . Debmalya Sanyal . Dibakar Biswas . Indira Maisnam . Kaushik Pandit . Moutusi Raychaudhuri . Nilanjan Sengupta . Partha Pratim Chakraborty . Pradip Mukhopadhyay . Pradip Raychaudhuri . Pranab Kumar Sahana . Purushottam Chatterjee . Rana Bhattacharjee . Ranen Dasgupta . Ravi Kant Saraogi . Salil Kumar Pal . Sarmishtha Mukhopadhyay . Satinath Mukhopadhyay . Soumik Goswami . Subhankar Chowdhury . Sujoy Ghosh . Working Group of the Endocrine Society of Bengal Received: June 4, 2020 Ó The Author(s) 2020
ABSTRACT Diabetic kidney disease (DKD) occurs in approximately 20–40% of patients with type 2 diabetes mellitus. Patients with DKD have a higher risk of cardiovascular and all-cause mortality. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and antihyperglycemic drugs form the mainstay of DKD management and aim to restrict
Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12871889. A. Roy Department of Endocrinology, Ramakrishna Mission Seva Pratishthan, Calcutta, West Bengal, India A. Maiti A. Sinha A. K. Basu P. P. Chakraborty Department of Endocrinology and Metabolism, Medical College and Hospital, Calcutta, West Bengal, India A. Baidya N. Sengupta P. K. Sahana S. Goswami Department of Endocrinology and Metabolism, Nil Ratan Sircar Medical College and Hospital, Calcutta, West Bengal, India D. Sarkar Dr Sarkar’s Clinic, Haora, West Bengal, India
progression to more severe stages of DKD. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) control hyperglycemia by blocking renal glucose reabsorption in addition to preventing inflammation, thereby improving endothelial function and reducing oxidative stress; consequently, this class of prescription medicines is emerging as an important addition to the therapeutic armamentarium. The EMPAREG OUTCOME, DECLARE TIMI 58, and CANVAS trials demonstrated the renoprotective effects of SGLT2i, such as restricting decline in glomerular filtration rate, in the progression of albuminuria, and in death due to renal causes. D. Sanyal Department of Endocrinology, KPC Medical College and Hospital, Calcutta, West Bengal, India D. Biswas P. Mukhopadhyay R. Bhattacharjee S. Mukhopadhyay S. Chowdhury S. Ghosh (&) Department of Endocrinology, IPGMER and SSKM Hospital, Calcutta, West Bengal, India e-mail: [email protected] I. Maisnam Department of Endocrinology, RG Kar Medical College and Hospital, Calcutta, West Bengal, India K. Pandit Department of Endocrinology, Belle Vue Clinic, Calcutta, West Bengal, India
Diabetes Ther
The renoprotection provided by SGLT2i was further confirmed in the CREDENCE study, which showed a 30% reduction in progression of chronic kidney disease, and in the DELIGHT study, which demonstrated a reduction in albuminuria with dapagli
Data Loading...
